Beactica selects BEA-17 as preclinical candidate from LSD1 program
Sep. 5, 2023
Beactica Therapeutics AB has selected BEA-17 as a preclinical candidate from its lysine demethylase 1 (LSD1) program targeting aggressive brain tumors and other cancers, and IND-enabling toxicology studies will now be initiated.